Cipla Launches Skin Treatment Drug In U.S.
An operator holds a syringe. (Photographer: Mikael Sjoberg/Bloomberg)

Cipla Launches Skin Treatment Drug In U.S.


Cipla Ltd. on Wednesday said it has launched Daptomycin Injection, used for treating complicated skin infections, in the U.S. market.

Daptomycin Injection is generic version of Cubicin, the drugmaker said in a statement.

"Cipla and its subsidiary Cipla USA, Inc announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin for Injection in the U.S.," the statement said.

According to IQVIA Health, Cubicin injection brand and generics had sales of around $606 million for the most recent 12 months ending in June 2019.

"The product is available for shipping immediately," the statement said.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.